News

On October 10, 2017, the U.S. Preventive Services Task Force (USPSTF) posted a draft recommendation statement on education about skin cancer prevention.

The FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adults with relapsed or refractory non-Hodgkin lymphoma (NHL). This CAR T-cell therapy breaks new ground in treatment for the disease.

Nearly a month after Hurricane Maria left a path of destruction in Puerto Rico, the island is still trying to pick of the pieces.

Radical prostatectomy was not associated with significantly lower all-cause or prostate-cancer mortality than observation.

Researchers from the Centers for Disease Control and Prevention and the National Cancer Institute assessed cancer incidence rates from 2005 to 2014 to identify trends for cancers associated with being overweight or obese.

In April 2017, the American Society of Clinical Oncology released a position statement, Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations, with the goal of educating healthcare providers about challenges faced by LGBTI individuals with cancer.

Improved treatment and early detection mean fewer women in the United States are dying from breast cancer, according to a study released by the American Cancer Society (ACS) that examined trends in the disease.

Survivors of non-Hodgkin lymphoma (NHL) are at a greater risk of heart failure than the general population, according to a recent study published in the Journal of Clinical Oncology.

The FDA approved abemaciclib (Verzenio) for use in combination with fulvestrant in women with HR+/HER2- advanced breast cancer with disease progression following endocrine therapy. The CDK4/6 inhibitor has also been approved as a monotherapy for patients with HR+/HER2- breast cancer with metastatic disease who have previously received endocrine therapy and chemotherapy.

FDA approval was given to a new regimen of cabazitaxel (Jevtana) to treat men with metastatic castration-resistant prostate cancer who previously received a docetaxel-containing regimen. The approval is for 20 mg/m2 every 3 weeks in combination with prednisone. The agency approved a dose of 25 mg/m2 every 3 weeks in this patient population in 2010.

Improved healthcare communication can often lead to better health outcomes for patients.

Patients with untreated advanced renal cell carcinoma (RCC) lived significantly longer without disease progression when they received the multikinase inhibitor cabozantinib (Cabometyx) as initial therapy versus sunitinib (Sutent), according to results of an independent review of the randomized CABOSUN trial reported at the 2017 ESMO Congress in Madrid.

The FDA announced today that it has approved the first biosimilar for the treatment of multiple types of cancer.

The FDA has granted an accelerated approval to copanlisib (Aliqopa) as a treatment for patients with relapsed follicular lymphoma who have received at least 2 least prior systemic therapies.

"This is a clear improvement in the outcome, with increased PFS—by about 11 months—consistent improvement in response rate, and decreases in the development of metastatic disease," said lead investigator Luis Paz-Ares, MD, chair, Medical Oncology Department, Hospital Universitario Doce de Octubre.

A new tool is helping healthcare providers determine who will benefit from palliative care starting early in the course of their treatment for cancer, according to the authors of a pilot study whose results were presented Sept. 9, during the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.

Can a class of drugs commonly prescribed to help lower cholesterol levels protect against breast cancer? A study recently presented at the European Society of Cardiology conference in Barcelona, Spain, offers interesting results.

Medical staff from the Hackensack Meridian Health system joined patients, survivors and their families for a day of fun and entertainment sponsored by the John Theurer Cancer Center.

Fertility preservation might be a bit more difficult for women with breast cancer who test positive for the BRCA gene mutation.

The authors noted that although some studies have shown improvement in breast cancer outcomes from extending treatment with AIs beyond the initial 5 years after diagnosis, there is not much research on the toxicity profile of extended use.

People being treated for cancer often experience “sticker shock” when they learn what charges they will be responsible for paying and/or when they receive billing invoices.

Updated United States Preventive Services Task Force (USPSTF) guidelines on prostate cancer screening were recently published in Cancer.

Socio-psychological factors have moved into the forefront of patients' concerns regarding chemotherapy effects, surpassing nausea and vomiting, which previously ranked as the top concern.

A group of researchers led by a physician from Memorial Sloan Kettering Cancer Center in New York City examined the natural history and growth kinetics of low-risk papillary thyroid cancer (PTC), defined as intrathyroidal tumors ≤1.5 cm in size.

The FDA has approved gemtuzumab ozogamicin (Mylotarg) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML).

Although they bring devastation to the whole community hit, catastrophes introduce a new level of difficulty for patients who are being treated for cancer.

Tisagenlecleucel (Kymriah), Novartis' newly approved CAR T-cell therapy, will be put on the market with a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists and that Novartis characterized as well below a price level that could be justified on cost.

The FDA issued a historic approval of the first Chimeric Antigen Receptor (CAR) T-Cell Therapy, authorizing the use of tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

Francisco J. Esteva, M.D., Ph.D. discussed genomic testing at the 16th Annual International Congress on the Future of Breast Cancer® (East).